



Dr. Daniel J. Wallace

Dr. Daniel J. Wallace is a Professor of Medicine at Cedars-Sinai Medical Center. Dr. Wallace has been practicing clinical rheumatology since 1979 with a special interest in systemic lupus erythematosus (SLE). He was fortunate to take over the practice of Dr. Edmund Dubois on his passing in 1985 and developed the largest single practitioner lupus cohort in the United States. His institution has participated in SLICC, the Lupus Clinical Trial Consortium, and the AROSE Criteria Committee. Dr. Wallace has been editor of the last 7 editions of Dubois' *Lupus Erythematosus*; the patient handbook, "The Lupus Book," has sold more than 125,000 copies. His center has performed more than 100 lupus clinical trials, biomarker, genetics, quality of life and SLE metric studies as well as 430 peer-reviewed publications and 28 book chapters. He has had first authorship on manuscripts relating to celecoxib, mycophenolate mofetil, leflunomide, baricitinib, belimumab and epratuzumab, and 8 publications (6 as lead author) in the *New England Journal of Medicine* and *Lancet*. Dr. Wallace's efforts have resulted in raising \$15 million for lupus research and establishing an endowed chair in rheumatology at Cedars-Sinai Medical Center. The center is excited by the prospect of participating in the lupus research initiatives.

Dr. Wallace has had the privilege of participating in rontilizumab, sifilmumab and baricitinib trials (with lead authorship for the latter two) and is co-PI of a NIH grant evaluating NAC for lupus which supports his knowledge and experience with anti-interferons and cell surface receptor inhibition (4-6 below). He is currently finalizing a NIH grant with Andras Perl as co-PI to study the role of N-acetylcystine (NAC) for SLE.